Finding drug targets through analysis of the platelet transcriptome

Current Pharmaceutical Design

Volumn 13, Issue 26, 2007, Pages 2662-2667

  McRedmond, James ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Affymetrix U95 Array; Platelet RNA; Platelet specific targets; Spotted Oligonucleotide Array; Translated Proteins

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 5; COMPLEMENTARY DNA; CYCLOPHILIN A; CYTOKINE; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; INTERLEUKIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; PROTEIN DERIVATIVE; PROTEIN KINASE INHIBITOR; RAB PROTEIN; RANTES; RECEPTOR PROTEIN; SECRETOGRANIN III; THIENOPYRIDINE DERIVATIVE; THROMBOCYTE FACTOR 4; TRANSCRIPTOME; UNCLASSIFIED DRUG; VASCULOTROPIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL SPECIFICITY; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DNA MICROARRAY; DRUG TARGETING; GENDER BIAS; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEOMICS; REVIEW; RNA STABILITY; RNA TRANSLATION; SERIAL ANALYSIS OF GENE EXPRESSION; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOGENESIS; THROMBOSIS; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS;

ANIMALS; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; PLATELET MEMBRANE GLYCOPROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 34548795461     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781662993     Document Type: Review

References (83)

1. Maree A, Fitzgerald DJ. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes: Where are we now? Semin Vasc Med 2003; 3: 385-90.
2. Luganova IS, Seits IF, Teodorovich VI. Metabolism in human thrombocytes. Biokhimiia 1958; 23: 405-11.
3. Warshaw AL, Laster L, Shulman NR. Protein synthesis by human platelets. J Biol Chem 1967; 242: 2094-7.
4. Booyse FM, Rafelson ME, Jr. Stable messenger RNA in the synthesis of contractile protein in human platelets. Biochim Biophys Acta 1967; 145: 188-90.
5. Kieffer N, Guichard J, Farcet JP, Vainchenker W, Breton-Gorius J. Biosynthesis of major platelet proteins in human blood platelets. Eur J Biochem 1987; 164: 189-95.
6. Konkle BA, Schick PK, He X, Liu RJ, Mazur EM. Plasminogen activator inhibitor-1 mRNA is expressed in platelets and megakaryocytes and the megakaryoblastic cell line CHRF-288. Arterioscler Tromb 1993; 13: 669-74.
7. Chang JD, Xu Y, Raychowdhury MK, Ware JA. Molecular cloning and expression of a cDNA encoding a novel isoenzyme of protein kinase C (nPKC). A new member of the nPKC family expressed in skeletal muscle, megakaryoblastic cells, and platelets. J Biol Chem 1993; 268: 14208-14.
8. Power CA, Furness RB, Brawand C, Wells TN. Cloning of a full-length cDNA encoding the neutrophil-activating peptide ENA-78 from human platelets. Gene 1994; 151: 333-4.
9. Hsu TC, Shore SK, Seshsmma T, Bagasra O, Walsh PN. Molecular cloning of platelet factor XI, an alternative splicing product of the plasma factor XI gene. J Biol Chem 1998; 273: 13787-93.
10. Steiner M, Baldini M. Protein synthesis in aging blood platelets. Blood 1969; 33: 628-33.
11. Ault KA, Rinder HM, Mitchell J, Carmody MB, Vary CP, Hillman RS. The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombopoiesis. Am J Clin Pathol 1992; 98: 637-46.
12. Balduini CL, Noris P, Spedini P. Belletti S, Zambelli A, Da Prada GA. Relationship between size and thiazole orange fluorescence of platelets in patients undergoing high-dose chemotherapy. Br J Haematol 1999; 106: 202-7.
13. Burk CD, Newman PJ, Lyman S, Gill J, Coller BS, Poncz M. A deletion in the gene for glycoprotein IIb associated with Glanzmann's thrombasthenia. J Clin Invest 1991; 87: 270-6.
14. Simsek S, Heyboer H, de Bruijne-Admiraal LG, Goldschmeding R, Cuijpers HT, von dem Borne AE. Glanzmann's thrombasthenia caused by homozygosity for a splice defect that leads to deletion of the first coding exon of the glycoprotein IIIa mRNA. Blood 1993; 81: 2044-9.
15. Schlegel N, Gayet O, Morel-Kopp MC, Wyler B, Hurtaud-Roux MF, Kaplan C, et al. The molecular genetic basis of Glanzmann's thrombasthenia in a gypsy population in France: Identification of a new mutation on the alpha IIb gene. Blood 1995; 86: 977-82.
16. Peretz H, Rosenberg N, Usher S, Graff E, Newman PJ, Coller BS, et al. Glanzmann's thrombasthenia associated with deletion-insertion and alternative splicing in the glycoprotein IIb gene. Blood 1995; 85: 414-20.
17. Peyruchaud O, Nurden A, Bourre F. Efficient RT-PCR on platelet mRNA after long-term storage. Br J Haematol 1997; 96: 183-5.
18. Franscini N, Bachli EB, Blau N, Fischler M, Walter RB, Schaffner A, et al. Functional tetrahydrobiopterin synthesis in human platelets. Circulation 2004; 110: 186-92.
19. Gnatenko DV, Dunn JJ, McCorkle SR, Weissmann D, Perrotta PL, Bahou WF. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood 2003; 101: 2285-93.
20. McRedmond JP, Park SD, Reilly DF, Coppinger JA, Maguire PB, Shields DC, et al. Integration of proteomics and genomics in platelets: A profile of platelet proteins and platelet-specific genes. Mol Cell Proteomics 2004; 3: 133-44.
21. Morris TD, Weber LA, Hickey E, Stein GS, Stein JL. Changes in the stability of a human H3 histone mRNA during the HeLa cell cycle. Mol Cell Biol 1991; 11: 544-53.
22. Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001; 154: 485-90
23. Fink L, Holschermann H, Kwapiszewska G, Muyal JP, Lengemann B, Bohle RM, et al. Characterization of platelet-specific mRNA by real-time PCR after laser-assisted microdissection. Thromb Haemost 2003; 90: 749-56.
24. Bugert P, Dugrillon A, Gunaydin A, Eichler H, Kluter H. Messenger RNA profiling of human platelets by microarray hybridization. Thromb Haemost 2003; 90: 738-48.
25. Rox JM, Bugert P, Muller J, Schorr A, Hanfland P, Madlener K, et al. Gene expression analysis in platelets from a single donor: evaluation of a PCR-based amplification technique. Clin Chem 2004; 50: 2271-8.
26. Hillmann RS, Harmon S, Park SDE, O'Brien J, Shields DC, Kenny D. Comparative RNA expression analyses from small-scale, single-donor platelet samples. J Thromb Haemost 2006; 4: 349-56.
27. Ye SQ, Usher DC, Zhang LQ. Gene expression profiling of human diseases by serial analysis of gene expression. J Biomed Sci 2002; 9: 384-94
28. + cells: identification of novel components of megakaryocytopoiesis. J Thromb Haemost 2006; 4: 848-60.
29. Matz M, Shagin D, Bogdanova E, Britanova O, Lukyanov S, Diatchenko L, et al. Amplification of cDNA ends based on template-switching effect and step-out PCR. Nucleic Acids Res 1999; 27: 1558-60.
30. Su AI, Cooke MP, Ching KA, Hakak Y, Walker JR, Wiltshire T, et al. Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci USA 2002; 99: 4465-70.
31. Gnatenko DV, Cupit LD, Huang EC, Dhundale A, Perrotta PL, Bahou WF. Platelets express steroidogenic 17beta-hydroxysteroid dehydrogenases. Distinct profiles predict the essential thrombocythemic phenotype. Thromb Haemost 2005; 94: 412-21.
32. Kunishima S, Kamiya T, Saito H. Genetic abnormalities of Bernard-Soulier syndrome. Int J Hematol 2002; 76: 319-27.
33. Harbig J, Sprinkle R, Enkemann SA. A sequence-based identification of the genes detected by probesets on the Affymetrix U133 plus 2.0 array. Nucleic Acids Res 2005; 33: E31.
34. Harrison P, Wilbourn B, Debili N, Vainchenker W, Breton-Gorius J, Lawrie AS, et al. Uptake of plasma fibrinogen into the alpha granules of human megakaryocytes and platelets. J Clin Invest 1989; 84: 1320-4.
35. O'Neill EE, Brock CJ, von Kriegsheim AF, Pearce AC, Dwek RA, Watson SP, et al. Towards complete analysis of the platelet proteome Proteomics 2002; 2: 288-305.
36. Marcus K, Immler D, Sternberger J, Meyer HE. Identification of platelet proteins separated by two-dimensional gel electrophoresis and analyzed by matrix assisted laser desorption/ionization-time of flight-mass spectrometry and detection of tyrosine-phosphorylated proteins. Electrophoresis 2000; 21: 2622-36.
37. Lian Z, Kluger Y, Greenbaum DS, Tuck D, Gerstein M, Berliner N, et al. Genomic and proteomic analysis of the myeloid differentiation program: Global analysis of gene expression during induced differentiation in the MPRO cell line. Blood 2002; 100: 3209-20.
38. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. The EPIC Investigators. Lancet 1994; 343: 881-6.
39. Chew DP, Bhatt DL, Topol EJ. Oral glycoprotein IIb/IIIa inhibitors: Why don't they work? Am J Cardiovasc Drugs 2001; 1: 421-8.
40. Goto S. Understanding the mechanism and prevention of arterial occlusive thrombus formation by anti-platelet agents. Curr Med Chem Cardiovasc Hematol Agents 2004; 2: 149-56.
41. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999; 100: 1667-72.
42. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-89.
43. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-cantrolled trial. Lancet 2005; 366: 1607-21.
44. Nanda N, Bao M, Lin H, Clauser K, Komuves L, Quertermous T, et al. Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activation. J Biol Chem 2005; 280: 24680-9
45. Lang D, Dohle F, Terstesse M, Bangen P, August C, Pauels HG, et al. Down-regulation of monocyte apoptosis by phagocytosis of platelets: Involvement of a caspase-9, caspase-3, and heat shock protein 70-dependent pathway. J Immunol 2002; 168: 6152-8.
46. Schafer A, Schulz C, Eigenthaler M, Fraccarollo D, Kobsar A, Gawaz M, et al. Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion. Blood 2004; 103: 407-12.
47. Abi-Younes S, Sauty A, Mach F, Sukhova GK, Libby P, Luster AD. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res 2000; 86: 131-8
48. Abi-Younes S, Si-Tahar M, Luster AD. The CC chemokines MDC and TARC induce platelet activation via CCR4. Thromb Res 2001; 101: 279-89.
49. Nijm J, Wikby A, Tompa A, Olsson AG, Jonasson L. Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease. Am J Cardiol 2005; 95: 452-6.
50. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5: 172-83.
51. Cohen P. Protein kinases - the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002; 1: 309-15.
52. Meijer L, Flajolet M, Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci 2004; 25: 471-80.
53. Manji HK, Chen G. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol Psychiatry 2002; 7(Suppl 1): S46-56.
54. Uckun FM, Mao C. Tyrosine kinases as new molecular targets in treatment of inflammatory disorders and leukemia. Curr Pharm Des 2004; 10: 1083-91.
55. Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost 2003; 1: 1602-12.
56. Li Z, Zhang G, Marjanovic JA, Ruan C, Du X. A platelet secretion pathway mediated by cGMP-dependent protein kinase. J Biol Chem 2004; 279: 42469-75.
57. Lipfert L, Haimovich B, Schaller MD, Cobb BS, Parsons JT, Brugge JS. Integrin-dependent phosphorylation and activation of the protein tyrosine kinase pp125FAK in platelets. J Cell Biol 1992; 119: 905-12
58. Hubbard GP, Wolffram S, Lovegrove JA, Gibbins JM. Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans. J Thromb Haemost 2004; 2: 2138-45.
59. Uckun FM, Vassilev A, Bartell S, Zheng Y, Mahajan S, Tibbles HE. The anti-leukemic Bruton's tyrosine kinase inhibitor alpha- cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism. Leuk Lymphoma 2003; 44: 1569-77.
60. Kuliopulos A, Mohanlal R, Covic L. Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation. Thromb Haemost 2004; 92: 1387-93.
61. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298: 1912-34.
62. Polgar J, Chung SH, Reed GL. Vesicle-associated membrane protein 3 (VAMP-3) and VAMP-8 are present in human platelets and are required for granule secretion. Blood 2002; 100: 1081-3.
63. Brogren H, Karlsson L, Andersson M, Wang L, Erlinge D, Jern S. Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood 2004; 104: 3943-8.
64. Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997; 94: 663-8.
65. Gear AR, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation 2003; 10: 335-50.
66. Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004; 103: 2096-104.
67. Reed GL. Platelet secretory mechanisms. Semin Thromb Hemost 2004; 30: 441-50.
68. Novak EK, Gautam R, Reddington M, Collinson LM, Copeland NG, Jenkins NA, et al. The regulation of platelet-dense granules by Rab27a in the ashen mouse, a model of Hermansky-Pudlak and Griscelli syndromes, is granule-specific and dependent on genetic background. Blood 2002; 100: 128-35.
69. von Hundelshausen P, Weber KS, Huo Y, Proudfoot AE, Nelson PJ, Ley K, et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001; 103: 1772-7.
70. Huo Y, Ley KF. Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med 2004; 14: 18-22.
71. Weyrich AS, Dixon DA, Pabla R, Elstad MR, McIntyre TM, Prescott SM, et al. Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets. Proc Natl Acad Sci USA 1998; 95: 5556-61.
72. Pabla R, Weyrich AS, Dixon DA, Bray PF, McIntyre TM, Prescott SM, et al. Integrin-dependent control of translation: Engagement of integrin alphaIIbbeta3 regulates synthesis of proteins in activated human platelets. J Cell Biol 1999; 144: 175-84.
73. Lindemann S, Tolley ND, Eyre JR, Kraiss LW, Mahoney TM, Weyrich AS. Integrins regulate the intracellular distribution of eukaryotic initiation factor 4E in platelets. A checkpoint for translational control. J Biol Chem 2001; 276: 33947-51.
74. Denis MM, Tolley ND, Bunting M, Schwertz H, Jiang H, Lindemann S, et al. Escaping the nuclear confines: Signal-dependent pre-mRNA splicing in anucleate platelets. Cell 2005; 122: 379-91.
75. Hawrylowicz CM, Santoro SA, Platt FM, Unanue ER. Activated platelets express IL-1 activity. J Immunol 1989; 143: 4015-8.
76. Kaplanski G, Porat R, Aiura K, Erban JK, Gelfand JA, Dinarello CA. Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event. Blood 1993; 81: 2492-5
77. Loppnow H, Bil R, Hirt S, Schonbeck U, Herzberg M, Werdan K, et al. Platelet-derived interleukin-1 induces cytokine production, but not proliferation of human vascular smooth muscle cells. Blood 1998; 91: 134-41.
78. Blackmore PF. Extragenomic actions of progesterone in human sperm and progesterone metabolites in human platelets. Steroids 1999; 64: 149-56.
79. Tavassoli M, Aoki M. Localization of megakaryocytes in the bone marrow. Blood Cells 1989; 15: 3-14.
80. Andresdottir MB, Sigurdsson G, Sigvaldason H, Gudnason V. Fifteen percent of myocardial infarctions and coronary revascularizations explained by family history unrelated to conventional risk factors. The Reykjavik Cohort Study. Eur Heart J 2002; 23: 1655-63.
81. Dogne JM, Hanson J, de Leval X, Pratico D, Pace-Asciak CR, Drion P, et al. From the design to the clinical application of thromboxane modulators. Curr Pharm Des 2006; 12(8): 903-23.
82. Francis CW. Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation. Curr Pharm Des 2005; 11(30): 3931-41.
83. Goertsches R, Serrano-Fernandez P, Moller S, Koczan D, Zettl UK. Multiple sclerosis therapy monitoring based on gene expression. Curr Pharm Des 2006; 12(29): 3761-79.